Connect with us

News

NAFDAC Approves AstraZeneca COVID-19 Vaccine For Use In Nigeria

Published

on

The National Agency for Food and Drug Administration and Control (NAFDAC) has approved a vaccine for use in the treatment and prevention of coronavirus in Nigeria.

The Oxford/AstraZeneca COVID-19 vaccine has now been approved for use in Nigeria.

The Director-General of NAFDAC, Dr. Mojisola Adeyeye made the announcement during a live briefing on Thursday.

NAFDAC DG, Dr. Mojisola Adeyeye briefs journalists on the use of AstraZeneca Vaccine in Nigeria

She said that the vaccine can be stored at 2 to 8-degree centigrade.

According to the DG, there are three additional vaccines undergoing evaluation, but the evaluation on Astrazeneca shows that the vaccine is effective against the UK variant of the virus which has been reported in Nigeria.

Dr Adeyeye disclosed that the South African variant has not been reported in Nigeria, adding that the agency has over 30 herbal medicine undergoing review for listing.

The vaccine was recently approved by the W.H.O for emergency use, in a press briefing, NAFDAC says it got the dossier of the vaccine a week ago, and the NAFDAC safety committee went to work immediately to evaluate its safety and efficacy for Nigerians.

The Oxford/AstraZeneca vaccine, also known as ChAdOx1 nCoV-19, or AZD1222, is a viral vector vaccine. Scientists used an adenovirus, originally derived from chimpanzees, and modified it with the aim of training the immune system to mount a strong response against SARS-CoV-2 (the virus that causes COVID-19).

Click to comment

You must be logged in to post a comment Login

Leave a Reply